Literature DB >> 6450254

The effect of streptozotocin-induced chronic diabetes mellitus on bone and mineral homeostasis in the rat.

R Shires, S L Teitelbaum, M A Bergfeld, M D Fallon, E Slatopolsky, L V Avioli.   

Abstract

Diabetes mellitus was induced in Lewis rats by streptozotocin, and these animals and control rats fed ad lib were studied after 7 weeks. At the time of sacrifice, nondecalcified histological sections of bone were prepared and subsequently quantitated by micromorphometric techniques. In addition, tibial alkaline phosphatase and mineral ash content were determined. The bones obtained from the diabetic animals are characterized by significant decrements in the quantities of osteoid and osteoclasts and by failure to acquire a tetracycline label. These histological features are attended by reduced quantities of urinary hydroxyproline and tibial alkaline phosphatase. As compared with control animals fed ad lib, diabetic rats are hyperphosphatemic and markedly hypercalciuric. Circulating alkaline phosphatase is also elevated and associated with a parallel increase in intestinal content of this enzyme. Although serum corticosterone levels are increased, diabetes is associated with decrements in both circulating immunoreactive parathyroid hormone and 1,25(OH)2D. We conclude that prolonged streptozotocin-induced diabetes mellitus in the rat results in reduced bone turnover. The relative roles that functional caloric deprivation, low circulating levels of 1,25(OH)2D, hypercalciuria, hypercortisolemia, and decreased blood parathyroid hormone levels play in the genesis of these skeletal abnormalities remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450254

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  24 in total

Review 1.  Osteoporosis and diabetes mellitus.

Authors:  Angela M Inzerillo; Solomon Epstein
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Diabetic bone disease.

Authors:  R Bouillon
Journal:  Calcif Tissue Int       Date:  1991-09       Impact factor: 4.333

Review 3.  Glucose metabolism in bone.

Authors:  Courtney M Karner; Fanxin Long
Journal:  Bone       Date:  2017-08-24       Impact factor: 4.398

4.  CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption.

Authors:  Katherine J Motyl; Michelle Raetz; Srinivasan Arjun Tekalur; Richard C Schwartz; Laura R McCabe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-02-23       Impact factor: 3.619

5.  Induction of endochondral bone by demineralized bone matrix from diabetic rats.

Authors:  R Landesman; A H Reddi
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

Review 6.  Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.

Authors:  Kathryn M Thrailkill; Charles K Lumpkin; R Clay Bunn; Stephen F Kemp; John L Fowlkes
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11       Impact factor: 4.310

Review 7.  The botanical molecule p-hydroxycinnamic acid as a new osteogenic agent: insight into the treatment of cancer bone metastases.

Authors:  Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2016-08-30       Impact factor: 3.396

8.  L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats.

Authors:  P Pennisi; G Clementi; A Prato; T Luca; G Martinez; R A Mangiafico; I Pulvirenti; F Muratore; C E Fiore
Journal:  J Endocrinol Invest       Date:  2009-05-05       Impact factor: 4.256

9.  Tetracycline administration increases collagen synthesis in osteoblasts of streptozotocin-induced diabetic rats: a quantitative autoradiographic study.

Authors:  T Sasaki; N S Ramamurthy; L M Golub
Journal:  Calcif Tissue Int       Date:  1992-05       Impact factor: 4.333

10.  Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study.

Authors:  J Aubia; S Serrano; L Mariñoso; L Hojman; A Diez; J Lloveras; J Masramon
Journal:  Calcif Tissue Int       Date:  1988-05       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.